Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS) (ABACCuS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04432272
Recruitment Status : Not yet recruiting
First Posted : June 16, 2020
Last Update Posted : July 10, 2020
Sponsor:
Information provided by (Responsible Party):
Matthew Sims, MD, PhD, William Beaumont Hospitals

Brief Summary:

The goal of this study is to evaluate the safety and effectiveness of COVID-19 convalescent plasma for the treatment of COVID-19. Plasma is the liquid part of blood that is left when all the blood cells have been removed. Convalescent means it is taken from people who were infected with COVID-19 and recovered. The use of this blood product to treat COVID-19 is investigational, which means the U.S. Food and Drug Administration has not yet approved it to be sold commercially. This is a human blood product collected by licensed blood banks. Donors of COVID-19 convalescent plasma must meet all standard blood donor criteria and must also meet all criteria set by the FDA for being a donor of COVID-19 convalescent plasma.

A total of 500 patients will take part in the study at 8 hospitals within Beaumont. Similar studies are being done at other centers, but they are not directly related to this study.

Participants will be assigned to a study group depending on how sick they are.

  • Group A: Those who require more than 6 liters (L) of supplemental oxygen but are not on a ventilator
  • Group B: Those who require a ventilator to preserve their life.

Both groups will receive one unit (approximately 200ml or just under 1 cup) of COVID convalescent plasma. The transfusion will be given over about 30 minutes via an IV. Blood samples will be taken prior to and one hour after the transfusion to measure participant antibodies against SARS-CoV-2 and a nasopharyngeal swab (deep in the nostril) will be taken to test for presence of the SARS-CoV-2 virus. One hour after the transfusion a blood sample will be taken to measure antibody levels to determine if the plasma caused the antibody level to rise. Similarly, blood samples will be taken to measure antibodies against SARS-CoV-2 and a nasopharyngeal swab will be taken to test for presence of the SARS-CoV-2 virus 1, 3 and every 7 days after the transfusion while the participant is in the hospital The participant's final health status will be determined on day 28. Hospital records will be monitored for 90 days after discharge to determine if the participant is readmitted to the hospital.


Condition or disease Intervention/treatment Phase
COVID-19 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infections Biological: COVID-19 convalescent plasma Phase 2

Detailed Description:

This trial will evaluate the efficacy and safety of SARS-CoV-2 convalescent plasma as treatment for confirmed COVID-19 respiratory disease (as defined in the inclusion criteria). Participants in both group A and group B will receive COVID-19 convalescent plasma. Group A will include hospitalized COVID-19 patients ages ≥18 years with respiratory symptoms, requiring >6 L of oxygen to maintain O2 saturation >92%. Patient may not require intubation, and may be admitted for no longer than 14 days. Group B will include hospitalized COVID-19 patients ages ≥18 years requiring intubation. Patients may be enrolled in group A within 14 days of admission to the hospital and may be enrolled in group B at any time after intubation. A total of 300 eligible subjects with significant oxygen requirements and 200 eligible subjects who require intubation will be included in the study. They will receive convalescent plasma from either a patient who has recovered from COVID-19 or from an asymptomatic carrier with confirmed IgG against SARS-CoV-2. Subjects will not be randomized. The amount of anti-SARS-CoV-2 IgG and IgA in any unit of plasma will not be known when the unit is assigned to the patient. This will allow us to examine the relationship between the amount of anti-SARS-CoV-2 antibody and outcomes. Analysis will be based on measurement of optical density of the IgG level in the unit of plasma the patient is randomly supplied by the blood bank. While investigators and patients will be aware the patient is receiving a unit of COVID-19 convalescent plasma, both the investigators and the patients will be blinded to the antibody content of that unit.

COVID-19 convalescent plasma (1 unit; ~200mL) will be produced by a blood bank licensed to produce plasma using standard screening and safety procedures. The product may be procured from patients who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA.

Participants at the eight Michigan hospitals comprising the Beaumont Health system may be eligible to participate. Study oversight and coordination will occur centrally, from the Infectious Disease Research Department at Beaumont's Royal Oak campus.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, single health system, non-randomized, open-label study.
Masking: None (Open Label)
Masking Description: No parties blinded as to receipt of study article. Participant, care provider and investigator blinded to actual antibody concentration in unit of plasma provided.
Primary Purpose: Treatment
Official Title: ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)
Estimated Study Start Date : July 14, 2020
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group A
Hospitalized COVID-19 patients ages ≥18 years with respiratory symptoms, requiring >6 L of oxygen to maintain oxygen saturation >92%. Patient may not require intubation, and may be admitted for no longer than 14 days.
Biological: COVID-19 convalescent plasma
Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit

Experimental: Group B
Hospitalized COVID-19 patients ages ≥18 years requiring intubation.
Biological: COVID-19 convalescent plasma
Participants will receive 1 unit of convalescent plasma procured from donors who have: 1) been symptom free for 14 days and screen negative via nasopharyngeal swab or 2) symptom free for at least 28 days or 3) individuals who have never had symptoms of COVID-19 but were found to have elevated anti-SARS-CoV-2 IgG by a serology test deemed to be of acceptable quality and fitting the current guidance by the FDA. Participants, clinicians, investigators and outcomes assessors will be blinded to the amount of anti-SARS-CoV-2 IgA and IgG present in each unit




Primary Outcome Measures :
  1. Avoidance of intubation at 28 days (group A) [ Time Frame: 28 days ]
    Count of group A participants (non-intubated participants requiring >6 L supplemental oxygen to maintain oxygen saturation >92% at time of study entry and who are admitted <14 days) who remain un-intubated

  2. Mortality (group B) [ Time Frame: 28 days ]
    Count of group B participants (participants who are intubated at study entry) who die


Secondary Outcome Measures :
  1. Cardio-circulatory arrest [ Time Frame: 28 days ]
    Count of participants who experienced cardio-circulatory arrest

  2. Patient Outcome at 28 days [ Time Frame: 28 days ]
    Patient Outcome as assessed on a 7-point ordinal scale, where 1= Not hospitalized, no limitations on activities, 2 =Not hospitalized, limitation on activities, 3= Hospitalized, not requiring supplemental oxygen, 4 =Hospitalized, requiring supplemental oxygen , 5 = Hospitalized, on non-invasive ventilation or high flow oxygen devices, 6 = Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), 7=Deceased. A lower number indicates a better outcome

  3. Renal failure [ Time Frame: 28 days ]
    Count of participants who develop or experience worsened renal failure as defined by RIFLE criteria, a 5-point scale where the categories are labeled: Risk-Injury-Failure-Loss-End stage renal disease, with Risk being the least severe and End stage renal disease being the most severe. The criteria for determination of stage are factors of serum creatinine and urine output. Numbers of participants worsening one or more RIFLE stages will be reported.

  4. Liver failure [ Time Frame: 28 days ]
    Count of participants who develop or experience worsened liver failure as measured by elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to 5x the upper limit of normal or significant worsening of current liver failure with rise in transaminases of >25%

  5. Cytokine Storm [ Time Frame: 28 days ]
    Count of participants who develop cytokine storm as measured by elevated markers of inflammation (elevated D-dimer, hypofibrinogenemia, hyperferritinemia), evidence of acute respiratory distress syndrome (ARDS) measured by imaging findings and mechanical ventilator requirements, and/or continuous fever (≥ 38.1 ° Celsius unremitting)

  6. Respiratory support [ Time Frame: 28 days ]
    Count of participants who require respiratory support in each of the following categories: nasal cannula, high flow nasal canula, non-rebreather, continuous positive airway pressure (CPAP), bilevel positive airway pressure (BIPAP), or intubation .

  7. Vasopressor medication support [ Time Frame: 28 days ]
    Count of participants who received pressor drugs, as ordered by treating physicians

  8. Length of ICU length of stay [ Time Frame: 28 days ]
    Length of ICU stay in days, for participants who entered ICU

  9. Intensive Care Unit (ICU) mortality [ Time Frame: 28 days ]
    Count of patients admitted to the ICU who die in ICU

  10. Hospital length of stay [ Time Frame: 28 days ]
    Length of hospital stay in days

  11. Ventilator free days [ Time Frame: 28 days ]
    Number of ventilator-free hospitalized days

  12. Intubation duration [ Time Frame: 28 days ]
    Length of intubation, measured in days

  13. Readmission [ Time Frame: 90 days ]
    Count of participants readmitted to hospital following index procedure hospital discharge

  14. Serum anti-SARS-CoV-2 IgG [ Time Frame: During hospitalization, a maximum of 28 days ]
    Count of participants positive for serum anti-SARS-CoV-2 IgG as assayed by the EUROIMMUN Anti-SARS-CoV-2 assay, evaluated semi-quantitatively by calculation of a ratio of the extinction of the patient sample over the extinction of a calibrator. This ratio is interpreted as: ratio < 0.8 is negative, ratio ≥ 0.8 to <1.0 is considered borderline, and ratio ≥ 1.1 is positive.

  15. SARS-CoV-2 RNA [ Time Frame: During hospitalization, a maximum of 28 days ]
    Count of participants with presence of SARS-CoV-2 RNA detected by reverse transcription polymerase chain reaction (RT-PCR) tested nasopharyngeal swabs.

  16. Mortality (group A) [ Time Frame: 28 days ]
    Count of group A participants (non-intubated participants requiring >6 L supplemental oxygen to maintain oxygen saturation >92% at time of study entry and admitted <14 days) who die

  17. Time from Transfusion to end of ventilator support (group B) [ Time Frame: During hospitalization, a maximum of 28 days ]
    Number of days from transfusion date until end of ventilator support for surviving group B participants (participants who are intubated at study entry)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must be 18 years of age or older.
  • Hospitalized with confirmed COVID-19 infection via COVID-19 SARS-CoV-2 RT-PCR testing.
  • Symptoms consistent with COVID-19 infection (fever, acute onset cough, shortness of breath) at time of screening.
  • Patient requires >6 L nasal cannula oxygen (Group A) or intubated (Group B).
  • Patient (or their legal authorized representative) is willing and able to provide written informed consent and comply with all protocol requirements.

Exclusion Criteria:

  • For patients in Group A admitted for >14 days
  • Female subjects with positive pregnancy test, breastfeeding, or planning to become --pregnant or breastfeed during the study period.
  • Receipt of pooled immunoglobulin in past 30 days.
  • Contraindication to transfusion or history of prior reactions to transfusion blood products.
  • Patients currently undergoing cancer treatment or those who are presently immunocompromised.
  • Patient who in the opinion of the investigator will not be a good study candidate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04432272


Contacts
Layout table for location contacts
Contact: Maureen Cooney, RN, BSN 248 551-0099 Maureen.Cooney@beaumont.org

Locations
Layout table for location information
United States, Michigan
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
Contact: Maureen Cooney, RN, BSN    248-551-0099    Maureen.Cooney@beaumont.org   
Principal Investigator: Matthew Sims, MD         
Sponsors and Collaborators
William Beaumont Hospitals
Investigators
Layout table for investigator information
Principal Investigator: Matthew Sims, MD PhD Beaumont Health
Layout table for additonal information
Responsible Party: Matthew Sims, MD, PhD, Director Infectious Disease Research, Beaumont Health; Professor of Internal Medicine and Foundational Medical Studies, OUWB School of Medicine, William Beaumont Hospitals
ClinicalTrials.gov Identifier: NCT04432272    
Other Study ID Numbers: 2020-198
First Posted: June 16, 2020    Key Record Dates
Last Update Posted: July 10, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Matthew Sims, MD, PhD, William Beaumont Hospitals:
therapeutic treatment
COVID-19 convalescent plasma
anti-SARS-CoV-2 antibody
IgA
IgG
COVID-19 pandemic
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Severe Acute Respiratory Syndrome
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases